Search
Quoin Pharmaceuticals Ltd
QNRXAdd to Watchlist
4.580USD
-0.130-2.76%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
314.38MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.76%
5 Days
+2.92%
1 Month
+6.76%
6 Months
-67.47%
Year to Date
-68.26%
1 Year
-47.95%
Key Figures
4.660Open
4.770High
39.13KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.06%Turnover Ratio
4.710Prev. Close
4.530Low
142.81KTurnover
LossP/E Static
35.83P/B
0.00%Div Yield TTM
-118.61%ROA
41.80052wk High
0.59Volume Ratio
-8.96MNet Profit
68.64MShares
-10.0599EPS TTM
1.58Beta
-231.18%ROE
4.55052wk Low
5.09%Amplitude
--Gross Margin
314.38MMarket Cap
1.22Reward/Risk
8.03%Risk Rate
TradingKey Stock Score of Quoin Pharmaceuticals Ltd
Currency: USD Updated: 2026-07-02Key Insights
Quoin Pharmaceuticals Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 198 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 21.40.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Quoin Pharmaceuticals Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Quoin Pharmaceuticals Ltd Highlights
StrengthsRisks
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -0.46, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 874.98K shares, increasing 29.68% quarter-over-quarter.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
21.400
Target Price
+354.35%
Upside Space
Quoin Pharmaceuticals Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Quoin Pharmaceuticals Ltd Info
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Ticker SymbolQNRX
CompanyQuoin Pharmaceuticals Ltd
CEOMyers (Michael)
Websitehttps://quoinpharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Quoin Pharmaceuticals Ltd (QNRX)?
The current price of Quoin Pharmaceuticals Ltd (QNRX) is 4.58.
What is the symbol of Quoin Pharmaceuticals Ltd?
The ticker symbol of Quoin Pharmaceuticals Ltd is QNRX.
What is the 52-week high of Quoin Pharmaceuticals Ltd?
The 52-week high of Quoin Pharmaceuticals Ltd is 41.80.
What is the 52-week low of Quoin Pharmaceuticals Ltd?
The 52-week low of Quoin Pharmaceuticals Ltd is 4.55.
What is the market capitalization of Quoin Pharmaceuticals Ltd?
The market capitalization of Quoin Pharmaceuticals Ltd is 314.38M.
Is Quoin Pharmaceuticals Ltd (QNRX) currently rated as Buy, Hold, or Sell?
According to analysts, Quoin Pharmaceuticals Ltd (QNRX) has an overall rating of Buy, with a price target of 21.40.
What is the Earnings Per Share (EPS TTM) of Quoin Pharmaceuticals Ltd (QNRX)?
The Earnings Per Share (EPS TTM) of Quoin Pharmaceuticals Ltd (QNRX) is -517.87.